NasdaqGM - Nasdaq Real Time Price USD

BioAtla, Inc. (BCAB)

0.3460

+0.0071

+(2.10%)

At close: April 22 at 4:00:01 PM EDT

0.3666

+0.02

+(5.95%)

After hours: April 22 at 7:21:26 PM EDT

Companies Like BioAtla (NASDAQ:BCAB) Could Be Quite Risky

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 24 days ago

BCAB
+2.10%
Q4 2024 Bioatla Inc Earnings Call

Q4 2024 Bioatla Inc Earnings Call

Thomson Reuters StreetEvents 25 days ago

BCAB
+2.10%
BioAtla Inc (BCAB) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

BioAtla Inc (BCAB) reports promising clinical progress and strategic initiatives, despite facing financial constraints and operational challenges.

GuruFocus.com 25 days ago

BCAB
+2.10%
BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study continues with data readout expected mid-2025; Dose expansion data readout anticipated 1H 2026 Mecbotamab vedotin (CAB-AXL-ADC) Q2W dosing regimen associated with exceptional overall survival (OS) with 66% and 58% of patients with mKRAS NSCLC alive at a landmark one-year and two-years, respectively, which exceeds the reported standard of care Ozuriftamab vedotin (CAB-ROR2-ADC) demonstrated compelling anti-tumor activity in treatment-refr

GlobeNewswire 26 days ago

BCAB
+2.10%
BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings

SAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced two abstracts accepted for poster presentations at the upcoming European Lung Cancer Congress (ELCC) 2025 Scientific Committee and Mayo Clinic Multidisciplinary Head and Neck Cancer Symposium 2025, to be held in Paris, France from March 26

GlobeNewswire last month

BCAB
+2.10%
BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025

SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, March 27, 2025 at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full-year ended December 31, 2024 and provide business highlights. Conference Call

GlobeNewswire last month

BCAB
+2.10%
BioAtla (BCAB) Upgraded to Buy: Here's What You Should Know

BioAtla (BCAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 3 months ago

BCAB
+2.10%
BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points

SAN DIEGO, Dec. 20, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company (“BioAtla” or the “Company”) focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it has entered into definitive agreements with certain institutional investors for the issuance and sale of 9,679,158 shares of its common stock in a registered direct offering. Each share of common stock o

GlobeNewswire 3 months ago

BCAB
+2.10%
Insiders Give Up US$66k As BioAtla Stock Drops To US$1.31

The recent price decline of 19% in BioAtla, Inc.'s ( NASDAQ:BCAB ) stock may have disappointed insiders who bought...

Simply Wall St. 4 months ago

BCAB
+2.10%
BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

Improved median overall survival (OS) for Mec-V treated patients with treatment-refractory non-small cell lung cancer (NSCLC) expressing mutated KRAS (mKRAS) as compared to Mec-V treated patient with treatment-refractory NSCLC expressing wild-type KRAS (wtKRAS) One-year OS was 58% for patients with NSCLC expressing mKRAS versus 23% for wtKRAS Mec-V antitumor activity observed across 9 different mKRAS variants Strong association of AXL expression by mKRAS NSCLC confirmed SAN DIEGO, Dec. 16, 2024

GlobeNewswire 4 months ago

BCAB
+2.10%
BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming International Association for the Study of Lung Cancer (IASLC) 2024 Hot Topic in Basic & Translational Science Meeting to be held in Washington, DC from December 13–15, 2024. Presentation Details: Title

GlobeNewswire 4 months ago

BCAB
+2.10%
BioAtla Inc (BCAB) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

BioAtla Inc (BCAB) reports promising clinical trial results and strategic FDA feedback, despite a significant cash decrease and ongoing financial uncertainties.

GuruFocus.com 5 months ago

BCAB
+2.10%
3 Promising US Penny Stocks With At Least $90M Market Cap

On November 7, 2024, U.S. markets continued their upward trajectory following a post-election rally, with the S&P 500 and Nasdaq reaching record highs as the Federal Reserve announced a rate cut. In such buoyant market conditions, investors often look beyond established giants to explore opportunities in lesser-known areas like penny stocks. Although the term "penny stocks" may seem outdated, these smaller or newer companies still offer potential for growth when backed by strong financials.

Simply Wall St. 5 months ago

CNDT

BCAB
+2.10%
III
BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress

Ozuriftamab vedotin (CAB-ROR2-ADC) Phase 2 trial in squamous cell carcinoma of the head and neck (SCCHN) continues to demonstrate durable clinical responses and median overall survival (OS) of approximately 9 months (ongoing) in a heavily pretreated population; actionable feedback received from the U.S. Food and Drug Administration (the “FDA”) regarding our proposed pivotal trial in second-line (2L) plus SCCHNEvalstotug (CAB-CTLA-4) in combination with PD-1 demonstrates tumor reduction in all ei

GlobeNewswire 5 months ago

BCAB
+2.10%
BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024

SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, November 7, 2024 at 4:30 p.m. ET to discuss its financial results for the third quarter ended September 30, 2024 and provide business highlights. Conference Call and Webcast I

GlobeNewswire 5 months ago

BCAB
+2.10%
BioAtla, Inc. (NASDAQ:BCAB) has caught the attention of institutional investors who hold a sizeable 39% stake

Key Insights Given the large stake in the stock by institutions, BioAtla's stock price might be vulnerable to their...

Simply Wall St. 5 months ago

BCAB
+2.10%
BioAtla, Inc. (BCAB): Among Michael Burry’s Top 10 Stock Picks Heading Into 2025

We recently compiled a list of the Michael Burry’s Top 10 Stock Picks Heading into 2025. In this article, we are going to take a look at where BioAtla, Inc. (NASDAQ:BCAB) stands against Michael Burry’s other stock picks. Established in May 2013, Scion Asset Management is a renowned and well-regarded California-based hedge fund founded by Michael […]

Insider Monkey 5 months ago

BCAB
+2.10%
^HSI
BioAtla Inc (BCAB) Q2 2024 Earnings Call Highlights: Strategic Progress Amid Financial Challenges

BioAtla Inc (BCAB) reports promising clinical advancements and strategic partnerships despite financial hurdles in Q2 2024.

GuruFocus.com 6 months ago

BCAB
+2.10%
BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held from November 8–10, 2024 at the George R. Brown Convention Center in Houston, TX. Presentation Details: Title: Updated results

GlobeNewswire 6 months ago

BCAB
+2.10%
BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress

SAN DIEGO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced acceptance of an abstract for oral presentation at the upcoming Society for Melanoma Research 21st International Congress (SMR), being held from October 10–13, 2024, in New Orleans, LA. Oral Presentation Details: Abstract title:Evalstotug (

GlobeNewswire 6 months ago

BCAB
+2.10%

Performance Overview

Return	BCAB	S&P 500 (^GSPC)
YTD	-41.46%	-10.10%
1-Year	-84.13%	+5.53%
3-Year	-90.60%	+23.78%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BioAtla, Inc. (BCAB)

Companies Like BioAtla (NASDAQ:BCAB) Could Be Quite Risky

Q4 2024 Bioatla Inc Earnings Call

BioAtla Inc (BCAB) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings

BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025

BioAtla (BCAB) Upgraded to Buy: Here's What You Should Know

BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points

Insiders Give Up US$66k As BioAtla Stock Drops To US$1.31

BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

BioAtla Inc (BCAB) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

3 Promising US Penny Stocks With At Least $90M Market Cap

BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress

BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024

BioAtla, Inc. (NASDAQ:BCAB) has caught the attention of institutional investors who hold a sizeable 39% stake

BioAtla, Inc. (BCAB): Among Michael Burry’s Top 10 Stock Picks Heading Into 2025

BioAtla Inc (BCAB) Q2 2024 Earnings Call Highlights: Strategic Progress Amid Financial Challenges

BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress

Performance Overview